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Abstract
Background: It has frequently been reported that Plasmodium vivax suppressed Plasmodium
falciparum and ameliorated disease severity in patients infected with these two species
simultaneously. The authors investigate the hypothesis that immunological responses stimulated by
P. vivax may play a role in suppressing co-infecting P. falciparum.
Methods: Sera, taken sequentially from one of the authors (YN) during experimental infection
with P. vivax, were added to in vitro cultures of P. falciparum. Cross-reactive antibodies against P.
falciparum antigens, and cytokines were measured in the sera.
Results: Significant growth inhibitory effects upon P. falciparum cultures (maximally 68% inhibition
as compared to pre-illness average) were observed in the sera collected during an acute episode.
Such inhibitory effects showed a strong positive temporal correlation with cross-reactive
antibodies, especially IgM against P. falciparum schizont extract and, to a lesser degree, IgM against
Merozoite Surface Protein (MSP)-119. Interleukin (IL)-12 showed the highest temporal correlation
with P. vivax parasitaemia and with body temperatures in the volunteer.
Conclusion: These results suggest the involvement by cross-reactive antibodies, especially IgM, in
the interplay between plasmodial species. IL-12 may be one of direct mediators of fever induction
by rupturing P. vivax schizonts, at least in some subjects. Future studies, preferably of
epidemiological design, to reveal the association between cross-reactive IgM and cross-plasmodial
interaction, are warranted.
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Background
A number of studies have reported that Plasmodium spe-
cies apparently suppressed each other, in population
[1,2], or in a mixedly-infected individual [3-8]. It is note-
worthy that the emergence of Plasmodium vivax in patients'
peripheral blood has led to a "total disappearance" of
Plasmodium falciparum, while passive transfer of P. falci-
parum-immune IgG exhibited weaker suppressive effects
on P. falciparum in these patients [9]. The severity of P. fal-
ciparum infection has been reported to be dramatically
ameliorated in patients simultaneously infected with P.
vivax [2,10]. Mutual suppression between Plasmodium par-
asites has been thoroughly reviewed [11-13]. These obser-
vations have led to speculation that the much lower
disease-specific mortality and case fatality rate from
malaria in Asia-Pacific region than in Africa may be due to
the presence of so-called "benign" P. vivax malaria
[14,15], because P. falciparum is by far the most dominant
in sub-Saharan Africa [16]. Therefore, understanding the
interaction of these Plasmodium species is important, espe-
cially because several P. vivax vaccines are currently being
developed. The authors hypothesized that the host immu-
nological reactions to infecting P. vivax might be playing
a role in this suppression of co-infecting P. falciparum.
Although such a notion has been long held [17-19], actual
data has been rarely available for human malaria. How-
ever, any study design that leaves ailing human volunteers
(other than the researcher) untreated is unacceptable
from a bioethical point of view. By contrast, "almost all of
the associated legal, ethical, and metaphysical problems
vanish" with self-recruitment of the researcher, according
to the founder of modern bioethics [20]. Hence, to exam-
ine the hypothesis, YN volunteered to be infected with P.
vivax, and his serum was collected sequentially during this
infection. The inhibitory effect of these sera upon P. falci-
parum growth was quantified by using an in vitro culture
technique. To illustrate the kinetics of the immunological
processes, immunological mediators including cross-reac-
tive antibodies against P. falciparum and cytokines in these
sera were also measured.
Case presentation
Human subjects
The volunteer (YN, an author) was a 35-year old Japanese
man. He had previously experienced Plasmodium infection
only once, when he was infected with P. vivax, one year
before the present study [21]. Control subjects were com-
posed of 21 healthy adult Bangkok residents (9 male and
12 female, median age: 33 years) who had never been
infected with any Plasmodium species.
Plasmodium vivax parasites
In January 2001, 2 ml of whole blood was obtained from
an adult patient who was infected with P. vivax near Thai-
land-Myanmar border. PCR confirmed that this blood
was infected with P. vivax but not with other Plasmodium
species [22]. Fifty female anopheline mosquitoes were fed
on this blood in a membrane feeder. One month later,
sporozoites were detected in the salivary glands of two
randomly selected mosquitoes.
Course of illness in the volunteer
The volunteer was challenged by another infected mos-
quito on day 0. The mosquito was tested by PCR, confirm-
ing the presence of P. vivax only. The volunteer was
continuously monitored in Mahidol University Hospital
for Tropical Diseases in Bangkok, a non-malarious region.
The volunteer experienced microscopically positive para-
sitaemias of P. vivax from day 14. From day 20, a regimen
of artemisinin (200 mg/day for 3 days) and doxycycline
(100 mg/day for 6 days) was administered to radically ter-
minate the blood-stage parasites. The blood collection
was resumed on day 29, when the anti-malarial drugs
should have been completely eliminated from the volun-
teer's blood [23,24]. Subsequently YN relapsed, and para-
sites were detected in the peripheral blood
microscopically on day 36. After experiencing an acute
phase, he was treated with chloroquine (1,500 mg on day
52; 500 mg on day 53 and 54), and with primaquine (15
mg per day for 14 days) to radically kill both the blood-
stage parasites and the hypnozoites. The illness, especially
headache, was subjectively much milder than in the previ-
ous infection one year before; nevertheless, the peak par-
asitaemia was three-times higher than the previous one.
Blood collection
Venous blood was collected every day as follows: (i) the
pre-challenge period (days -6 to 0); (ii) the initial infec-
tion period (days 1 to 20); (iii) the relapse period (days 29
to 53). Blood was collected 7, 29 and 29 times during the
periods (i), (ii) and (iii), respectively. The sera collected
during the period (i) provided the baseline. The volunteer
was phlebotomized once per day when the body temper-
ature did not show a noticeable elevation; otherwise twice
per day (one at a peak of body temperature and one at
about 12 hours after the peak). Blood was allowed to
coagulate at 25°C for 20 minutes, and centrifuged. Serum
was preserved at -70°C until use. No drugs were adminis-
tered from day -20 and throughout the entire period of the
infection, except for the above medications.
In vitro cultures of Plasmodium falciparum
Plasmodium falciparum was cultured in vitro, in each of the
volunteer's sera, as follows. K1 strain of P. falciparum was
synchronized into the ring form stage [25], and subse-
quently mixed with the incomplete medium and the puri-
fied type-O red blood cells, so that the P. falciparum
parasitaemia was set to 0.5% and the haematocrit was
adjusted to 50%. In the each well on a 96-well flat-bot-
tomed plate, 10 μl of this parasite preparation, 45 μl of the
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incomplete medium, and 35 μl of each of the volunteer's
sera were mixed (final volume 90 μl; hematcrit 5.6%;
serum concentration 39% (v/v)). The plate was incubated
under 5% CO2pressure at 37°C. After 24 hours, 60 μl of
the supernatant was replaced by 35 μl of the the same
serum and 45 μl of incomplete medium. After a further 28
hours, two thin films were prepared from each well. The
percent reduction from the baseline was defined as the
growth inhibition of the each serum. As a result, the vol-
unteer's sera collected during the relapse period exhibited
growth inhibitory effects, significantly elevated above the
baseline level (Figure 1c). This was particularly marked
between days 46 and 51 (mean: 42%, maximum: 68%),
and to a lesser degree, between days 33 and 35.
Measurement of cross-reactive antibodies
To investigate the degree of cross-reactive immunity in the
sera, we measured IgM and IgG levels against P. falciparum
schizont extract and Merozoite Surface Protein (MSP)-119
of P. falciparum. ELISA was carried out as previously
described [26]. P. falciparum schizont extract and MSP-
119(Wellcome sequence) were obtained as described in
[26-28]. Each IgG plate contained a standard dilution
series of a laboratory reference hyper-immune adult Gam-
Course of illness in the volunteer and in vitro growth inhibition on P. falciparum exhibited by the volunteer's seraFig r 1
Course of illness in the volunteer and in vitro growth inhibition on P. falciparum exhibited by the volunteer's 
sera. (a) Plasmodium vivax parasitaemias (percentage of infected red blood cells) determined microscopically in the volunteer 
are represented by a line, while detection of P. vivax by PCR is denoted by horizontal black bars. (b) Body temperatures meas-
ured at the time of phlebotomies are shown. (c) The solid line represents the average of in vitro growth inhibition obtained 
from four cultures, while the dotted lines represent standard errors. The broken line denotes the upper 95% confidence limit 
of the baseline sera. Days of high values are denoted on the symbols in this and subsequent figures. Day 0 is the day of chal-
lenge.
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bian plasma pool. For IgM, a standard dilution series of
non-specific IgM purified from human serum (Sigma-
Aldrich) was coated in one set of wells. Of note, IgM val-
ues against P. falciparum schizont extract and MSP-119
were elevated after day 47 (Figure 2a,b). The temporal cor-
relation between pairs of time-series variables, such as
growth inhibitory effect and antibody level, were quanti-
fied as follows. First, simple linear regression was applied.
Next, since the blood was sampled at non-random time
points and temporally non-independent, we also
employed Prais-Winsten's method for time-series regres-
sion [29]. In doing so, the time-axis was divided into dis-
crete time-steps of a fixed length (half day, one day and
two days). When a time-step included more than one
sample, the averaged value was used. As a result, the in
vitro growth inhibitory effects on P. falciparum and the lev-
els of IgM against P. falciparum (especially, schizont
extract) showed strong temporal correlation, in any time-
step lengths examined (Table 1).
Cytokines
Interferon (INF) -γ, Interleukin (IL) -1β, IL-2, IL-4, IL-6,
IL-12p40, TNF-α were measured, at least in duplicate,
using commercial ELISA kits (Diaclone, Besancon). TNF-
α showed highly variable values among multiple meas-
urements (data not shown). Among the cytokines exam-
ined, IL-12 showed the highest correlation with P. vivax
parasitaemia (compare Figure 3a vs Figure 1a). When IL-
12 was regressed against the parasitaemia, Prais-Winsten's
R2 at half-day time-steps was 0.62 (P < 0.0001). This sug-
gested that IL-12 is closely associated with schizont rup-
ture. IFN-γ was extremely spiky and appeared only in the
first few paroxysms (defined as a body temperature above
37.5°C), both in initial and relapse periods (Figure 3b).
Other cytokines showed weaker association with parox-
ysm or parasitaemia (Figure 3c,d,e).
Conclusion
Host antibody responses against Plasmodium are heteroge-
neous across different ethnicities [30], ages and accumu-
lated exposure [31]. A single observation from one
volunteer cannot, therefore, be generalized. However,
despite this caveat, the present study suggests the possibil-
ity that cross-reactive antibodies, especially IgM, in an
individual who has been infected only with P. vivax sup-
press growth of P. falciparum. Although IgM does not
undergo a process of affinity maturation, this is compen-
sated for by the fact that it is a pentamer. At least one
report found that IgM exhibited a stronger neutralizing
effects on Plasmodial merozoites than did IgG [32].
Indeed, this lower specificity may make IgM more likely
show cross-species reactivity. The short-lived nature of
IgM may also explain why mutual suppression across Plas-
modial species is rather transient [6] (also reviewed in
[33]), or why immunization with one species rarely pro-
tected the vaccinees from other species [34]. In vivo, IgG-
mediated cellular mechanisms [9,35], may also play an
important role in the cross-Plasmodium interaction.
IL-12, which showed the highest correlation with P. vivax
parasitaemia, is hence likely to be (one of) the most direct
mediator(s) bridging from rupturing schizonts to fevers. It
was reported that IL-12 and IFN-γ synergistically enhance
the parasiticidal activities of peripheral blood mononu-
clear cells [36-41]. Therefore, the sharp peaks of INF-γ
under the presence of IL-12 observed in the volunteer
could mount an early in vivo defense against blood-stage
parasites, and may contribute to the suppressive effect of
P. vivax on P. falciparum.
Collectively, these results suggest a possibility that P. vivax
infections may suppress P. falciparum in multiple ways
including cross-reactive IgM and cytotoxicity-inducing
cytokines. To thoroughly prove that Plasmodium-specific
IgM is playing a major role in cross-Plasmodium suppres-
Table 1: Results of analyses which regressed in vitro Plasmodium falciparum growth inhibition against each cross-reactive antibody 
level.
Simple linear regression Prais-Winsten's regression
half-day†† one-day†† two-day††
(N = 64†) (N = 62) (N = 50) (N = 27)
IgM against schizont extract R2 = 0.50
(P < 0.0001)
R2 = 0.43
(P < 0.0001)
R2 = 0.44
(P < 0.0001)
R2 = 0.56
(P < 0.0001)
IgM against MSP-119 R2 = 0.38
(P < 0.0010)
R2 = 0.16
(P = 0.0016)
R2 = 0.18
(P = 0.0022)
R2 = 0.16
(P = 0.036)
IgG against szhitont extract R2 = 0.22
(P = 0.0001)
R2 = 0.011
(P = 0.41)
R2 = 0.026
(P = 0.27)
R2not obtained
(P = 1.0)
IgG against MSP-119 R2 = 0.029
(P = 0.18)
R2 = 0.079
(P = 0.063)
R2 = 0.22
(P = 0.0006)
R2 = 0.070
(P = 0.18)
Each regression analysis was conducted against single independent variable. †One serum sample (day 6) was not available for antibody 
measurements and growth inhibition assays. †† For Prais-Winsten's analysis, the data was aggregated in each time-step of half-day, one-day or two-
day lengths.
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Cross-reactive antibodies against Plasmodium falciparum antigensFigure 2
Cross-reactive antibodies against Plasmodium falciparum antigens. (a) IgM against P. falciparum schizont extract, (b) 
IgM against P. falciparum Merozoite Surface Protein (MSP)-119, (c) IgG against P. falciparum schizont extract, and (d) IgG against 
P. falciparum MSP-119. The solid line represents the concentration of IgM, or the titer of IgG as compared to the hyper-immune 
pooled serum (titer = 1). The broken line denotes the upper 95% confidence limit obtained from the baseline, while the mean 
and confidence interval in the control subjects are denoted as the vertical bar overlapping Y axis.
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Serum cytokine levelsFig re 3
Serum cytokine levels. Concentrations of (a) IL-12, (b) IFN-γ, (c) IL-6, (d) IL-1β, (e) IL-4 (all in pg/ml) (solid lines). The bro-
ken line denotes the upper limit of 95% confidence interval obtained from the baseline, while the mean and confidence interval 
in the control subjects are shown as the vertical bar overlapping Y axis.
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sion, such specific IgM should have been purified. Such
studies should be part of any further work to test the
hypothesis proposed here, preferably within an epidemi-
ologically appropriate framework.
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